AU4177196A - Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage - Google Patents

Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Info

Publication number
AU4177196A
AU4177196A AU41771/96A AU4177196A AU4177196A AU 4177196 A AU4177196 A AU 4177196A AU 41771/96 A AU41771/96 A AU 41771/96A AU 4177196 A AU4177196 A AU 4177196A AU 4177196 A AU4177196 A AU 4177196A
Authority
AU
Australia
Prior art keywords
chronic
treatment
skin damage
inflammatory modulators
recalcitrant skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU41771/96A
Inventor
Wai Yuen John Chen
Alan Andrew Rogers
Michael Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU4177196A publication Critical patent/AU4177196A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU41771/96A 1994-12-07 1995-11-28 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage Abandoned AU4177196A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9424708A GB9424708D0 (en) 1994-12-07 1994-12-07 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
GB9424708 1994-12-07
PCT/EP1995/004715 WO1996017606A1 (en) 1994-12-07 1995-11-28 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Publications (1)

Publication Number Publication Date
AU4177196A true AU4177196A (en) 1996-06-26

Family

ID=10765563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41771/96A Abandoned AU4177196A (en) 1994-12-07 1995-11-28 Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage

Country Status (3)

Country Link
AU (1) AU4177196A (en)
GB (1) GB9424708D0 (en)
WO (1) WO1996017606A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241282A (en) * 1996-05-21 2002-08-28 Bayer Yakuhin Ltd Medicine for treating allergic dermatitis
WO2001087834A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5798209A (en) * 1980-12-09 1982-06-18 Kowa Co Remedy for dermatopathy for external use
US4925873A (en) * 1988-09-01 1990-05-15 E. R. Squibb & Sons, Inc. Method of treating skin injuries using thromboxane A2 receptor antagonists

Also Published As

Publication number Publication date
WO1996017606A1 (en) 1996-06-13
GB9424708D0 (en) 1995-02-01

Similar Documents

Publication Publication Date Title
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU7623096A (en) Use of epinastine in the treatment of pain
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU1542895A (en) Surface treatment
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
AU2672795A (en) Benzopyrans and their use as therapeutic agents
AU5590696A (en) Use of quinones in the treatment of cancer or AIDS
AU4774597A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
AU2387097A (en) Substituted benzylamines and their use for the treatment of depression
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU3124295A (en) Surface treatment techniques
AU4347696A (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
AU4177196A (en) Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU2068295A (en) Skin treatment composition
AU5537296A (en) The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
AU3634595A (en) Bis-oxazolidines and their use
ZA958558B (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
AU4812393A (en) Use of rapamycin in the treatment of aids
AU2160697A (en) Nsaids in the treatment of pruritus
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
IL127350A0 (en) Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
AU1485197A (en) Diamines in the treatment of arrhythmia